Triana Biomedicines

News

Protego's $130m for amyloidosis drug, and other financings

Our latest crop of biotech financings has nine-figure rounds for Protego and Triana, with Excelsior Sciences and SciNeuro also raising new funds.

News

Pfizer sticks $1.5bn on Triana's molecular glue tech

Big pharma's interest in using protein degradation as a therapeutic strategy continues with a wide-ranging deal between Pfizer and US biotech Triana Biomedicines that could be worth $1.5 bi

News

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Editor's Picks